



ASX & Media Release

## **PAT-DX1 to be Showcased at International DDR Inhibitor Summit**

**Melbourne, Australia, 20 January 2020:** Patrys Limited (ASX:PAB, “Patrys” or the “Company”), a therapeutic antibody development company, is pleased to announce the upcoming presentation of scientific data regarding its lead candidate, PAT-DX1, at the PARP & DNA Damage Response (DDR) Inhibitors Summit in Boston, USA.

### **Key highlights**

- Dr. James Hansen from the Yale School of Medicine will present PAT-DX1 pre-clinical data at the PARP & DDR Inhibitors Summit in Boston, USA
- The PARP & DDR Summit includes presentations from global pharmaceutical companies including Merck, Bayer and Astra Zeneca
- The presentation highlights the potential applications of PAT-DX1 as a single agent, a sensitising agent for DNA-damaging therapies, and as a delivery vehicle for linked nanocarriers and drugs

Dr. James Hansen from the Yale School of Medicine will present at the PARP & DDR Inhibitors Summit at 2pm (EST) on Thursday, 30 January 2020. Ms. Suzy Jones, Patrys Non-Executive Director, will also be attending the summit. Ms. Jones has an extensive network and more than 20 years’ experience in business development and executing licensing transactions globally.

Dr. Hansen’s presentation, titled *“Targeting the DDR with a Nuclear-Penetrating Anti-DNA Autoantibody”*, will highlight the clinical potential of Patrys’ lead candidate, PAT-DX1. Dr. Hansen’s presentation will demonstrate how PAT-DX1 preferentially localises to tumours, crosses the blood brain barrier, binds to DNA and inhibits the DDR and why it is synthetically lethal to DDR-deficient cancer cells. The summit will also provide an opportunity to showcase the potential application of PAT-DX1 as a single agent against DDR-deficient tumours, as a sensitising agent for DNA-damaging therapies and as a nanoparticle conjugation agent (PAT-DX1-NP) to enable targeted delivery of therapeutics to improve patient outcomes.

The summit will gather the global pioneers of DDR inhibitor development and explore PARP inhibitor development, combination strategy and use in expanded indications to optimise future DDR therapy. The summit examines emerging and innovative approaches which target the DDR agnostically, to build a picture of the future DDR therapy landscape.

**Patrys Chief Executive Officer and Managing Director, Dr. James Campbell said:** *“The summit represents an important opportunity to showcase PAT-DX1’s unique mechanism of action, ability to cross the blood brain barrier and considerable promise as a potential anti-cancer therapeutic to an audience of global industry leaders. The growing international recognition of our technology reflects the leading position that Patrys and Yale are establishing in the DDR therapeutics space.”*

**-Ends-**



This announcement is authorised for release by the Board of Directors of Patrys Limited.

**For further information, please contact:**

**General enquiries**

James Campbell  
CEO & MD  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

**Media enquiries:**

Kyahn Williamson  
WE Communications  
P: +61 3 8866 1214  
[kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)

**Registered Office Address**

Level 4, 100 Albert Road  
South Melbourne VIC 3205

**About Patrys Limited**

Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its Deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. More information can be found at [www.patrys.com](http://www.patrys.com).